When someone asks me what laser unit I use in my practice, the conversation almost always drifts toward power output within thirty seconds. What wattage is it? Is it a Class IV? Is higher wattage better? I understand why practitioners and pet owners fixate on watts. Power output is the number that gets marketed, the number on the spec sheet and the sales brochure. It is measurable and impressive-sounding. A 25-watt unit sounds more capable than a 5-watt unit the same way a 500-horsepower engine sounds faster than a 200-horsepower engine.
The analogy breaks down completely when you apply it to therapeutic laser therapy, or more precisely, photobiomodulation (PBM). Watts describe the rate of energy delivery. They tell you nothing about how much energy a specific tissue actually received, at what depth, over what area, or whether the biological response you were targeting was achieved. In over fifteen years working hands-on in canine rehabilitation, I have reviewed enough poorly dosed laser protocols to know that watts-first thinking causes more treatment failures than almost any other variable. This post is my attempt to give other rehabilitation practitioners the full clinical picture.
What Photobiomodulation Actually Does at the Cellular Level
Before dosing can make sense, the mechanism has to make sense. PBM works by delivering photons of specific wavelengths to tissue, where they are absorbed by chromophores inside cells. The primary chromophore in mammalian tissue is cytochrome c oxidase, the terminal enzyme in the mitochondrial electron transport chain. When photons are absorbed by cytochrome c oxidase, the result is increased ATP synthesis, reduced reactive oxygen species, and modulation of nitric oxide release.
The downstream effects are the ones we are targeting clinically: reduced pro-inflammatory cytokines, increased growth factor expression, accelerated collagen synthesis and fibroblast proliferation, and measurable analgesic effects through changes in nociceptor sensitivity. These are not theoretical effects. The mechanism has been documented across multiple peer-reviewed studies using in-vitro and in-vivo models.
The critical point for dosing is this: the photon must reach the target chromophore. If your energy does not penetrate to the tissue depth where cytochrome c oxidase is located in sufficient density, the biological cascade does not begin. This is where wavelength and fluence become the real conversation, not wattage alone.
Why Joules Per Square Centimeter Is the Real Metric
Fluence, expressed as joules per square centimeter (J/cm2), is the dose metric that actually governs PBM outcomes. It describes the total energy delivered per unit area of tissue. Watts tells you the rate of delivery. Joules tells you the cumulative amount. Joules per square centimeter tells you how concentrated that energy is across the treatment surface.
The relationship is straightforward mathematically. Fluence equals power density (watts per square centimeter) multiplied by time in seconds. So a 10-watt laser applied to a 10 cm2 spot delivers a power density of 1 W/cm2. Applied for 60 seconds, that delivers 60 J/cm2. Applied for 30 seconds, you are at 30 J/cm2. Same laser, same tissue, very different biological response.
PBM follows what researchers refer to as a biphasic dose-response relationship, sometimes called the Arndt-Schulz curve in biological systems. Low doses stimulate. Adequate doses produce the target therapeutic effect. Excessive doses can inhibit the very processes you are trying to activate. I have seen this clinically with acute inflammatory conditions where practitioners applying high fluence rates intended for deep tissue work ended up with patients showing transient pain flares post-treatment. The biology was not responding to the watts. It was responding to the joules per centimeter squared delivered to superficial nociceptors that did not need that level of energy.
The World Association for Laser Therapy (WALT) and the North American Association for Photobiomodulation Therapy (NAALT) both publish dosing guidelines that reference J/cm2 as the primary dosing parameter. Any laser protocol that leads with wattage and does not specify fluence is missing the most important number.
Depth of Penetration: Wavelength Determines Where Energy Lands
Wavelength is the variable that determines how deep photons travel into tissue before they are absorbed or scattered. This is basic optical physics applied to biology, and it has profound implications for protocol design in canine patients.
The therapeutic window for PBM sits between approximately 600 nanometers and 1100 nanometers. Within that range, tissue penetration varies significantly. Red wavelengths in the 630 to 700 nm range penetrate relatively shallowly, reaching superficial dermal tissue and subdermal structures effectively. Near-infrared wavelengths in the 800 to 1000 nm range penetrate more deeply into muscle, periarticular soft tissue and bone. This is the range most relevant for targeting deep musculoskeletal structures in dogs.
In canine patients, the anatomy adds complexity that practitioners often underestimate. Coat color and density, subcutaneous fat depth and muscle mass all affect how much energy actually reaches the target tissue. A heavily muscled Labrador Retriever with a dense black coat requires a fundamentally different approach than a lean Greyhound. Dark pigmentation absorbs more photons at the surface, which means less energy reaches deeper structures at equivalent fluence settings. I routinely part the coat and apply the handpiece in direct contact with skin for deep targets, and I account for adipose tissue depth when calculating fluence for patients with significant subcutaneous fat.
For deep targets like the hip joint in a large-breed dog, I am working with near-infrared wavelengths and adjusting fluence upward to compensate for the optical path length through overlying tissue. For superficial wound bed management or incision line support post-TPLO, I scale back to lower fluence with red or near-red wavelengths to match the target depth.
Treatment Time Calculations That Actually Hold Up Clinically
Treatment time is a derived variable, not a starting point. I am genuinely concerned when I hear practitioners say they treat a stifle for four minutes because that is what the protocol card says. Four minutes means nothing without knowing power density, spot size and target fluence.
The calculation I use for every treatment plan starts with the target fluence in J/cm2 based on the condition and tissue depth. I then calculate the treatment area in square centimeters. From there, total joules required equals target fluence multiplied by treatment area. Time in seconds equals total joules divided by power output in watts.
Walk through it with real numbers. Target fluence for a post-operative stifle at day 14 using near-infrared: approximately 6 to 8 J/cm2 based on tissue depth and phase of healing. Treatment area approximated at 20 cm2. Total joules needed: 120 to 160 joules. At 8 watts continuous, treatment time equals 15 to 20 seconds if I maintain stationary contact. Because I typically scan with a moving handpiece over a larger anatomical area, my effective power density is lower and time scales accordingly. Each pass rate and distance from skin changes the math and must be accounted for.
This is why I calculate before I treat, every time. The preset programs on commercial units are useful starting points but they are not a substitute for understanding the underlying physics of your specific patient, your specific target tissue and the phase of tissue healing you are addressing.
The Canine Evidence Base for PBM
I want to be honest about where the canine literature stands in 2026. The evidence base is growing but it is not uniform across conditions. The strongest canine-specific evidence supports PBM for wound healing acceleration, post-operative pain and swelling management and osteoarthritis analgesia.
Research published in peer-reviewed veterinary journals including the Veterinary Surgery journal and American Journal of Veterinary Research has examined PBM in the context of TPLO recovery, soft tissue wound management and chronic musculoskeletal pain. Studies examining PBM in canine osteoarthritis have documented improvements in pain scores using validated instruments including the Canine Brief Pain Inventory and force plate gait analysis, which are the objective outcome measures I find most credible for clinical application.
The evidence from human physical medicine and human photobiomodulation research is substantially deeper, and much of our dosing rationale in veterinary rehabilitation draws from that literature with appropriate species-specific adjustments. The American College of Veterinary Sports Medicine and Rehabilitation (ACVSMR) has increasingly incorporated PBM into its clinical practice frameworks, and the Canine Rehabilitation Institute addresses laser dosing in its curriculum with the species-specific considerations that distinguish veterinary from human application.
What I want practitioners to take from the literature is this: the studies that showed positive outcomes specified their dosing in J/cm2 and wavelength. The studies that showed null results frequently used inadequate fluence for the target tissue depth. Wattage alone was never the distinguishing variable between studies that worked and studies that did not.
Common Dosing Errors I See in Canine Rehabilitation Practice
After years of consulting with other practitioners and reviewing cases where laser therapy did not produce the expected clinical response, the errors I encounter most frequently fall into a few consistent categories.
The first is treating fluence as constant regardless of target depth. Using the same 6 J/cm2 setting for a superficial incision line and a hip joint in a 35-kilogram dog is not evidence-based dosing. The optical path lengths are entirely different and the delivered energy at the target tissue is not comparable.
The second error is not accounting for coat and pigmentation. A thorough physical assessment before treatment should include an evaluation of coat density, coat color over the treatment area and estimated subcutaneous tissue depth. These factors directly modify effective fluence at the target.
The third is treating too frequently in the acute inflammatory phase with high fluence. The biphasic dose-response curve means that aggressive dosing during acute inflammation can suppress the early inflammatory cascade that is necessary for proper tissue repair initiation. I am very conservative with fluence in the first 48 to 72 hours post-operatively or post-injury.
The fourth is failing to reassess treatment response systematically. I use objective outcome measures at every relevant session including gait analysis observation, pain behavior scoring using the Glasgow Composite Pain Scale where applicable and owner-reported functional questionnaires. If the tissue response is not tracking as expected after three to four sessions, I reassess my dosing calculation before I conclude that laser therapy is not working for that patient.
Building a Defensible Laser Protocol for Your Canine Patient
A defensible therapeutic laser protocol in canine rehabilitation is built on documented clinical reasoning, not factory presets. Here is the framework I work through for every new patient receiving PBM.
Start with the diagnosis and tissue target. Define specifically what structure you are treating, its anatomical depth in this patient and the phase of tissue healing or pathology. These three variables determine your wavelength selection and target fluence range.
Calculate fluence based on published dose ranges for the condition and adjust upward for tissue depth, coat pigmentation and adipose tissue thickness. The WALT dosing recommendations provide a useful starting framework for many musculoskeletal and wound healing indications.
Calculate treatment time from your power output and your treatment area, not from a preset program. Document your calculation in the patient record. This is what makes your protocol defensible to the supervising DVM and reproducible by other practitioners who treat the patient in your absence.
Define your frequency and course of treatment based on tissue healing timelines. Acute post-operative management may warrant daily treatment for the first week. Chronic osteoarthritis management might begin with two to three sessions per week for four weeks before transitioning to maintenance frequency guided by patient response.
Reassess with objective measures at defined intervals. Adjust frequency and fluence based on clinical response. A protocol that does not adapt to patient response is not a clinical protocol. It is a recipe being followed without engagement.
Therapeutic laser is a genuinely powerful modality when the dosing is sound. The watts on the spec sheet are only the starting point for a calculation that has several more variables in it. Understanding those variables is what separates skilled PBM practice from running a machine.